SIGY (Sigyn Therapeutics) Total Liabilities: $6.05 Mil (As of Sep. 2025)


What is Sigyn Therapeutics Total Liabilities?

Sigyn Therapeutics SIGY +22.62% Total Liabilities is $6.05 Mil as of Sep. 2025. The stock has 3 warning signs investors should review.

Sigyn Therapeutics's Total Liabilities for the quarter that ended in Sep. 2025 was $6.05 Mil.

Sigyn Therapeutics's quarterly Total Liabilities increased from Mar. 2025 ($5.19 Mil) to Jun. 2025 ($5.49 Mil) and increased from Jun. 2025 ($5.49 Mil) to Sep. 2025 ($6.05 Mil).

Sigyn Therapeutics's annual Total Liabilities increased from Dec. 2022 ($2.24 Mil) to Dec. 2023 ($3.73 Mil) and increased from Dec. 2023 ($3.73 Mil) to Dec. 2024 ($4.67 Mil).

Sigyn Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Sigyn Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sigyn Therapeutics Total Liabilities Chart

Sigyn Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.60 0.98 2.24 3.73 4.67

Sigyn Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.35 4.67 5.19 5.49 6.05

Sigyn Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Sigyn Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4.615+(0.056+4.8572257327351E-17
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=4.67

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=0.214--4.458
=4.67

Sigyn Therapeutics's Total Liabilities for the quarter that ended in Sep. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=3.989+(2.063+0.00099999999999989
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=6.05

Total Liabilities=Total Assets (Q: Sep. 2025 )-Total Equity (Q: Sep. 2025 )
=0.136--5.917
=6.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $6.05 Mil mean?
Sigyn Therapeutics (SIGY) has a Total Liabilities of $6.05 Mil as of Sep. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Sigyn Therapeutics and its competitors.
Is Sigyn Therapeutics' Total Liabilities too high?
Sigyn Therapeutics' current Total Liabilities is $6.05 Mil.
How does Sigyn Therapeutics' Total Liabilities compare to RGBP and ENDV?
Sigyn Therapeutics' Total Liabilities of $6.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Sigyn Therapeutics and its competitors. Sigyn Therapeutics's current Total Liabilities is $6.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sigyn Therapeutics stock overvalued right now?
Sigyn Therapeutics (SIGY) has a current Total Liabilities of $6.05 Mil. The current Total Liabilities is $6.05 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Sigyn Therapeutics (SIGY), the current Total Liabilities is $6.05 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sigyn Therapeutics Business Description

Address 2468 Historic Decatur Road, Suite 140, San Diego, CA, USA, 92106
Sigyn Therapeutics Inc is a development-stage therapeutic technology company. Its business focus is the clinical advancement of Sigyn Therapy, a multi-function blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the cause of hospital deaths world-wide. To support widespread implementation, the company designed Sigyn Therapy to be a single-use disposable device that is deployable on the world-wide infrastructure of hemodialysis and continuous renal replacement therapy machines already located in hospitals and clinics.